Overview

This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent in patients with solid tumors, hepatocellular carcinomas (HCC), and castrate-resistant prostate cancer (CRPC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
OBI Pharma, Inc